Dermabin oinment 15g (Salicylic acid) — Made in Ukraine — Free Delivery

Betamethasone dipropionate is a synthetic fluorinated corticosteroid that has anti-inflammatory, antipruritic and vasoconstrictor effects. When applied topically, salicylic acid has a keratolytic effect.

Absorption of betamethasone dipropionate by the body is possible mainly after prolonged use on a large surface of the skin.

Clinical characteristics.

For local treatment of dermatoses sensitive to corticosteroids, such as chronic, erythematous or hyperkeratosis psoriasis and other dermatoses of an erythematous-squamous nature, in particular, seborrheic dermatitis (eczema), dry eczema in the desquamative phase, lichenification.

The preparation is contraindicated in patients with hypersensitivity to active substances or to any other component of the preparation. as well as for rosacea, acne, skin reactions after vaccination, perioral dermatitis, widespread plaque psoriasis, perianal and genital itching, varicose veins, diaper dermatitis, skin manifestations of syphilis, chickenpox, skin tuberculosis, other bacterial and fungal infections of the skin antibacterial and antifungal therapy, with herpes zoster, herpes common, molluscum contagiosum, dermatomycosis.

Active ingredients: betamethasone, salicylic acid;

1 g of ointment contains 0.64 mg of betamethasone dipropionate, which is equivalent to 0.5 mg of betamethasone, and 30 mg of salicylic acid;

auxiliary substances: petroleum jelly, petroleum jelly.

The preparation is not intended for use in ophthalmology. avoid contact with eyes, mucous membranes, wound surfaces and ulcers.

If irritation or hypersensitivity occurs during the use of the preparation, treatment should be discontinued.

In the presence of infection, appropriate therapy should be prescribed.

With the disappearance of dandruff or keratinization, treatment is continued only with corticosteroids.

Any side effects that are observed with the use of systemic corticosteroids, including inhibition of the function of the adrenal cortex, can also be observed with topical application of glucocorticosteroids, especially in children.

The systemic absorption of corticosteroids or salicylic acid with topical application will be higher if the treatment is carried out on large surfaces of the body or when using occlusive dressings. Appropriate precautions should be taken in such cases or with prolonged use, especially when treating children.

With the development of excessive dryness or increased skin irritation, the preparation  should be discontinued.

Topical corticosteroids can cause psoriasis for a variety of reasons, including recurrence of symptoms followed by the development of tolerance, the risk of pustular psoriasis and local systemic toxicity due to a decrease in the protective function of the skin. Patients with impaired liver function are more sensitive to systemic influences. Careful observation of the patient is necessary.

Topical corticosteroids can distort the clinical picture.

A relapse is possible if treatment is interrupted, as well as an exacerbation of the infection and a delay in healing.

Application of the preparation to areas with atrophied skin is contraindicated.

Since the safety of using topical corticosteroids for pregnant women has not been established, the appointment of these preparations is possible only if the expected benefit to the expectant mother clearly outweighs the potential threat to the fetus. preparations in this group are contraindicated for pregnant women in high doses and for a long time.

At present, it is unclear whether topical corticosteroids can penetrate into breast milk as a result of systemic absorption when applied topically, therefore, when deciding whether to stop breastfeeding or discontinue the preparation, the need to prescribe the preparation  should be taken into account.